FOXN3 and breast cancer: Patients with high FOXN3 expression had longer OS and RFS times than those with low FOXN3 expression in HCC, osteosarcoma and breast cancer patients.9, 12, 19 The results of this study suggested that downregulation of FOXN3 correlates with poor OS and RFS of non‐APL.